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Recently, we developed a non-hemodynamic dopamine derivative N-octanoyl dopamine 
(NOD) which has profound anti-inflammatory effects in vitro. Since NOD also protects rats 
from ischemic acute kidney injury (AKI), the present study tested if NOD is able to modulate 
cellular immunity for potential use as T cell suppressive agent. To this end, T cells were 
stimulated by anti-CD3/CD28 or PMA/ionomycin in the presence or absence of different 
concentrations of NOD. T cell proliferation, activation markers, intracellular cytokine 
expression and activation of transcription factors were assessed. 
While T cell proliferation was significantly inhibited by NOD at day 3, proliferation was 
restored at day 7 or later depending on the NOD concentration used. Inhibition of proliferation 
was reflected by a diminished CD25 expression and switch from naive to memory T cells. Early 
T cell receptor activation events were unaffected, yet NF-κB and AP-1 were strongly inhibited 
by NOD. The inhibitory effect of NOD seemed to be dependent on its redox activity since N-
octanoyl tyramin, a redox inactive NOD derivative, did not influence proliferation. NOD 
displayed synergistic effects with calcineurin inhibitors on T cell proliferation. Our data 
demonstrate that NOD displays T cell suppressive activity. In keeping with its anti-
inflammatory action and its beneficial effect on ischemia-induced AKI, NOD may be an 
interesting drug candidate to prevent calcineurin inhibitor related side effects. 
NOD transiently inhibits T cell proliferation 
115 
Introduction                                                                                                              
The introduction of new immunosuppressant drugs in recent years has allowed for a reduction 
in acute rejection rates paralleled by a highly significant improvement in short-term kidney graft 
survival. Yet, this improvement has not translated into significant changes in chronic graft loss 
[261, 262], and hence, late graft failure continues to be a frequent cause of readmission onto 
dialysis programs and re-entry onto the waiting list.  
Acute vascular rejection and chronic rejection, i.e. interstitial fibrosis and tubulus atrophy 
(IFTA), are the main causes for renal graft failure and loss [263]. IFTA is a clinicopathological 
entity characterized by fibrosclerosis of the different renal structures leading to progressive 
decline of renal function after kidney transplantation [264]. Although the molecular 
mechanisms that underlie the pathophysiology of IFTA remain far from clear, it seems to result 
from the concerted action of immunological and non-immunological factors [265]. The use of 
calcineurin inhibitors (CNI) are amongst others identified as a non-immunologic risk factor, 
associated with nephrotoxic [266] and neurotoxic [267] side effects. Attempts to minimize or 
wean patients off of CNI have shown that improvement in renal function is often obtainable but 
only at the expense of increased alloimmune reactions [268]. Developing a calcineurin 
inhibitor-based long-term maintenance immunosuppressive drug regimen with improved long-
term tolerability is therefore a highly desirable endeavor. 
In a prospective randomized multicenter trial we have shown that donor treatment with low-
dose dopamine has a salutary effect on immediate kidney graft function [45]. In a subgroup 
analysis this was translated into a better graft survival for recipients who obtained a renal 
allograft with prolonged cold preservation time. Graft survival was also improved in heart 
allograft recipients [150] but did not affect outcome after liver transplantation [45]. Based on 
in vitro experiments, we have postulated that this protective effect is independent of the 
hemodynamic action of dopamine and requires the redox-active catechol structure [156]. 
Moreover we have shown that conjugation of n-octanoic acid to the amine side chain of 
dopamine, which likely impairs adrenergic and dopaminergic receptor engagement, results in a 
far more protective compound [162]. N-octanoyl dopamine (NOD) not only protects cells and 
tissues against prolonged hypothermic preservation, it also strongly inhibits platelet function 
[269] and activation of NF-κB in vitro and improves acute kidney injury (AKI) in vivo [178]. 
In keeping with the notion that NF-κB plays a pivotal role in cellular immunity, in the present 
study we further investigated the potential benefit of NOD in transplantation medicine by 
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assessing the influence of NOD on T cell activation in vitro. To this end, we tested if NOD 
inhibits T cell proliferation, how this is accomplished in mechanistic terms and if NOD can 
decrease CNI concentrations without reducing T cell suppression.  
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Materials and Methods 
Isolation of human PBMC, T cells and T cell subsets 
Human peripheral blood mononuclear cells (PBMC) from healthy adult volunteer donors were isolated 
by centrifugation of venous blood on Ficoll-Hypaque density gradients (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden). T cells were enriched from human PBMCs applying Miltenyi Biotec’s PAN 
T cell Isolation kit II according to manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Untouched CD 4+ cells were further purified using positive CD8+ selection (CD8 
microbeads) and naive and memory populations were obtained by positive selection with CD45RO 
microbeads. Purity of more than 98% was controlled by FACS-analysis. T cells or PBMCs were 
cultured with RPMI 1640 supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, 
Pasching, Austria) and 1% penicillin and streptomycin (Sigma-Aldrich, Munich, Germany). 
N-octanoyl dopamine and N-octanoyl tyramine synthesis 
N-octanoyl dopamine (NOD) and N-octanoyl tyramine (NOT) were synthesized from commercially 
available precursors as previously described [162]. Briefly, octanoic acid was dissolved in 
tetrahydrofuran and N-ethyldiisopropylamine before conversion to their mixed anhydride by the 
reaction with ethyl chloroformate. For coupling the crude mixed anhydride and dopamine 
hydrochloride were dissolved in N,N-dimethylformamide in the presence of diisopropylamine. 
Sodium hydrogen carbonate and sodium sulfite were added and after evaporation of the solvent the 
product was obtained. N-octanoyl tyramine was synthesized according to NOD using the analog mixed 
anhydride coupled to tyramine as reaction component. Both products were purified by two-fold 
recrystallization from dichloremethane which was proved by thin layer chromatography. Samples were 
dissolved in ethanol, investigated by 1H-NMR spectroscopy (Bruker AC250) and yielded spectra in 
accordance with the expected structure. Vehicle concentration in cell culture was less than 0.1 ‰ and 
had no influence on results (vehicle control not shown). 
T cell proliferation assay 
Human PBMCs (106 cells/ml) were cultured in 200 µl of complete medium in 96-well, U-bottom 
microtiter plates (CELLSTAR-greiner bio-one, Kremsmünster, Austria). The cells were stimulated for 
various time intervals with anti-CD3/CD28 Dynabeads (Invitrogen Dynal AS, Oslo, Norway) in the 
presence of different concentrations of NOD or NOT and pulsed with 0.2 µCi of [6-3H]thymidine/well 
(Perkin Elmer, Groningen, The Netherlands) during last 16 h of culture. All conditions were tested on 
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six plicate culture wells. Incorporated 3H-thymidine was assessed by scintillation counting in a liquid 
scintillation counter (LS 6500, Beckman Coulter, Krefeld, Germany). 
Flowcytometric analyses  
For cytotoxicity assays, measurement of CD4, CD25 and CD45RO expression and reactive oxygen 
species (ROS)-production PBMC (106 cells/ml) were stimulated in 24-well plates with anti-
CD3/CD28 Dynabeads (Invitrogen Dynal AS, Oslo, Norway) in the presence of different 
concentrations of NOD. Following 3 or 7 days of culture the cells were harvested and stained for CD3, 
CD4, CD25, CD45RO using a specific mAb (all BD Biosciences, San Jose, CA, USA) or with mAb 
against Annexin V and the death cell indicator 7AAD (both Biolegend, Fell, Germany).  
To evaluate ROS production, cells were loaded with 8 μM 6-carboxy-2',7'-dichlorodihydrofluorescein 
diacetate, di(acetoxymethyl ester) (H2-DCFDA) according to the supplier’s instruction (Invitrogen, 
Karlsruhe, Germany). Cells were stimulated with anti-CD3/CD28 Dynabeads (Invitrogen Dynal AS, 
Oslo, Norway) in the presence or absence of 100 µM NOD. Fluorescence recordings were performed 
by FACS directly after 5 or 20 minutes of stimulation. ROS was defined as increased mean 
fluorescence intensity relative to control cells not stimulated with anti-CD3/CD28. 
For measurement of intracellular cytokines cells were stimulated with PMA (50 ng/ml)/ionomycine 
(1µg/ml) (both from Sigma-Aldrich, St. Louis, MO, USA) for 4 h in the presence or absence of 100 
µM of NOD. GolgiPlug (BD Bioscience, Heidelberg, Germany) was used to prevent cytokine 
secretion. Cells were fixed and permeabilized using Cytofix/Cytoperm (BD Bioscience, Heidelberg, 
Germany) before staining with specific mAb (all BD Biosciences, San Jose, CA, USA). 
Cell cycle analysis was assessed after 3 days of anti-CD3/CD28 stimulation. DRAQ5 (Biostatus Lim., 
Shepshed, UK) staining was used at a final concentration of 10 µM according to the supplier’s 
protocol. For all experiments cells were analyzed on a FACS Calibur flow cytometer (BD Biosciences, 
Heidelberg, Germany). At least 50,000 gated events were collected per sample and data were analyzed 
by Flowjo software (Tree Star, Inc., Ashland, OR, USA). T cells were gated either by CD3 positivity 
in the fluorescence/SSC-dotplot or by their typical location in the FSC/SSC-dotplot. 
Cellular staining and fluorescence microscopy 
Human T cells (2 x 104 cells/slide) were seeded on adhesive slides (Marienfeld-superior, Lauda-
Königshofen, Germany). Cells were stimulated with Dynabeads anti-CD3/CD28 (Invitrogen Dynal 
AS, Oslo, Norway) in the presence or the absence of 100 µM NOD for 2 h and subsequently fixed 
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with 4% paraformaldehyde and stained with mouse anti-human CD3 clone UCHT1 (eBioscence, 
Frankfurt am Main, Germany) and goat anti-mouse IgG1 FITC (BD Bioscience, Heidelberg, 
Germany). Cells were analyzed using a laser-scanning-microscope TCS SP2 (Leica, Mannheim, 
Germany). 
Western blots 
Human T cells (106 cells/ml) were stimulated for various time intervals with anti-CD3/CD28 
Dynabeads (Invitrogen Dynal AS, Oslo, Norway) in the presence or the absence of 100 µM of NOD. 
Cells were then washed with PBS and proteins were extracted in 100 µl of lysis buffer (10 mM HEPES 
(pH 7.9 at 25°C), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 0.5 mM DTT, 200 µM PMSF (dissolved 
in ethanol). Samples were subjected to electrophoresis on 10% SDS-polyacrylamide gels. Separated 
proteins were transferred to nitrocellulose membranes (0.5 A at 100 V, 6°C) for 1 h. Blots were blocked 
in Tris buffered saline (TBS) containing 0.1% Tween 20 and 5% BSA overnight at 6°C. Staining of 
blots was performed by standard operating procedures using anti-cyclin D1 (Santa Cruz 
Biotechnology, Heidelberg, Germany), anti-pLck and anti-pZAP70 monoclonal antibodies (both Cell 
Signaling Technology, Inc., Beverly, MA, USA). To confirm equal protein loading, membranes were 
stripped and re-probed with monoclonal anti-β-actin (Abcam, Cambridge, UK) for cyclin D or anti-
Lck and anti-ZAP70 (both Cell Signaling Technology, Inc., Beverly, MA, USA) antibodies. Detection 
of immunoreactive bands was performed using an ECL-system (Cell Signaling Technology, Inc., 
Beverly, MA, USA). 
Nuclear protein extraction and electrophoretic mobility shift assay (EMSA) 
Human T cells (106 cells/ml) were stimulated for various time intervals with 50 ng/ml PMA and 1 
µg/ml ionomycin (Sigma-Aldrich, St. Louis, MO, USA) in the presence or absence of 100 µM NOD. 
Nuclear extracts were prepared as previously described [270] and protein concentrations were 
determined by Bradford assay. NF-κB (5’-AGTTGAGGGGACTTTCCCAGGC-3’) or AP-1 (5'-
CGCTTGATG ACTCAGCCGGAA-3') double-stranded consensus oligonucleotide (both Promega 
Corp., Madison, WI, USA) were end-labeled with γ-32P-ATP using T4-polynucleotide kinase, ethanol 
precipitated and finally dissolved in 20 µl of distilled water. 1 µl of 32P-labeled probe (~30,000 cpm) 
and 15 μg of nuclear extracts were added to a binding reaction mixture containing: 10 mmol/l HEPES 
(pH 7.5), 0.5 mmol/l EDTA, 70 mmol/l KCl, 2 mmol/l DTT, 2% glycerol, 0.025% NP-40, 4% Ficoll, 
0.1 mol/l PMSF, 1 mg/ml bovine serum albumin and 0.1 mg/ml poly di/dc and incubated for 30 min 
at room temperature. DNA–protein complexes were separated by electrophoresis through a 5% non-
denaturing acrylamide: bis-acrylamide gel in 0.5 × Tris–borate (TBE) /EDTA for 3 h at 220 V. Gels 
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were analyzed by autoradiography using an Amersham Hyperfilm ECL (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden). In each experiment, specificity of binding was demonstrated by preincubation 
with cold consensus (100x excess of unlabeled oligonucleotides) or mutated NF-κB or AP-1 
oligonucleotides to the nuclear extracts. In addition, supershifts were performed by adding p50, p52, 
p65, RelB, c-Rel, c-jun and c-fos antibodies to the samples (all Santa Cruz Biotechnology, Heidelberg, 
Germany). 
Luminol oxidation assay 
To test the anti-oxidant capacity of NOD and NOT the luminol oxidation assay was used. To this end, 
serial dilutions of NOD or NOT were added to a complete volume of 200 µl of reaction mixture 
containing 0.005 U horseradish peroxidase (HRP) and 20 µM of luminol. The reaction was 
immediately recorded in a luminometer (Lumat LB9507, Berthold, Bad Wildbad, Germany) after 
addition of 0.01% H2O2.  
Statistics 
Data is expressed as mean ± standard deviation (SD). For proliferation assays, cell cycle analysis, cap 
formation and ROS measurements statistical analysis were performed using Student’s t-test with 
previous testing of equality of variances (SigmaPlot 11.0, Systat Software GmbH, Erkath, Germany). 
If equality test failed the Kruskal-Wallis-test was performed. For western blot average optical densities 
of bands of all blots were assessed using ImageJ 1.46 and Student’s t-test was performed on ratio of 
cyclin D/β-actin or phosphorylated/total protein as mentioned above.  A p-value of less than 0.05 was 
considered as significant.  
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Results 
NOD inhibits T cell activation transiently 
PBMC were stimulated with anti-CD3/CD28 for 3 days in the presence of different 
concentrations of NOD (range 0 – 200 µM). As shown in Figure 1a, NOD inhibited T cell 
proliferation in a dose-dependent fashion. Similar results were obtained when purified CD3+ T 
cells were used or when PMA/ionomycin was used as mitogen (data not shown). NOD inhibited 
naive and memory CD4+ T cells (Figure 1b and c) as well as CD8+ T cells to similar degrees 
(Figure 1d). To assess if T cell proliferation was consistently inhibited in time, 3H-thymidine 
was added at different time points following anti-CD3/CD28 stimulation. While in the absence 
of NOD T proliferation peaked much later as indicated by a shift in the kinetic curves (Figure 
1e), which was clearly dependent on the NOD concentration (Peak proliferation: NOD 50 µM 
at day 7, NOD 100 µM at day 11, NOD 200 µM at day 15). The extent of T cell proliferation, 
as assessed by the height of the proliferation peak, was not affected by the lower NOD 
concentration, but was significantly reduced when 200 µM of NOD was used (Figure 1e). Since 
at 200 µM of NOD T cell proliferation was consistently impaired in time and was associated 
with an increase in trypan blue positive cells (data not shown) a direct toxic effect at this 
concentration could not be excluded. Although this was not observed when lower 
concentrations were used. Annexin V/7AAD stainings were performed to formally exclude that 
low concentrations of NOD were also toxic (Figure 1f). For all further experiments NOD 























Figure 1: Influence of NOD on T cell proliferation and activation. PBMCs. (a) purified naive (b) and 
memory (c) CD4+ , as well as CD8+ (d) T cells were stimulated for three days with anti-CD3/CD28 in the 
presence of different concentrations of NOD and pulsed with 0.2 µCi [3H]-thymidine for the last 16 hours 
of culture. The results of a representative experiment are depicted and expressed as mean [3H]-
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of 6 experiments were performed with essentially similar results. Significance was defined as p<0.05 (* 
p<0.001 compared to the medium control). (e) PBMCs were treated as described in (a) and proliferation 
was assessed at different time points following anti-CD3/CD28 stimulation. The results of a 
representative experiment are depicted and expressed as mean [3H]-thymidine incorporation in counts 
per minute (cpm) ± SD of 6 replicate wells for each condition. A total of three different experiments 
were performed. (f) PBMCs were stimulated as described in (a) for 7 days in the presence or absence of 
100 µM of NOD. Cell death was assessed by FACS using Annexin V/7AAD staining. Note that no 
significant difference in double positive cells between medium and NOD treated cells was observed. 
Similar findings were obtained after 1 and 3 days of stimulation. 
 
In line with a transient inhibition of T cell proliferation we observed that the T cell activation 
marker CD25 and the switch from naive CD45RA to memory CD45RO cells were affected 
when cells were stimulated in the presence of NOD. After 3 days of anti-CD3/CD28 stimulation 
both the amount of CD3+ T cells expressing CD25 or the memory marker CD45RO were 
diminished in the presence of NOD, but this was normalized at day 7 (Figure 2a). To assess if 
cell cycle progression was involved in NOD-mediated delay in T cell proliferation, cell cycle 
analysis was performed. While cell cycle progression in the absence of NOD revealed that three 
days after stimulation approximately 42%, 34% and 24% of the cells were in the G0/G1-phase, 
S-phase and G2/M-phase respectively, in the presence of NOD there was a dose dependent 
increase of T cells that did not pass beyond the G0/G1-phase (Figure 2b). G1-arrest in NOD-
treated cells was further confirmed by cyclin D1 expression, which significantly declined within 












Figure 2: NOD mediates cell cycle arrest in T cells. (a) T cells were stimulated for 3 or 7 days with anti-
CD3/CD28 in the presence of different concentrations of NOD. CD25 and CD45RO expression was 
assessed by FACS analysis. The table below each histogram shows the percentage of positive cells for 
CD25 and CD45RO respectively. The filled histogram represents cells directly stained and analysed after 
isolation. Depicted is one representative experiment out of four. (b) T cells were stimulated with anti-
CD3/CD28 in the presence of different concentrations of NOD and stained with DRAQ5 at day 3. Cell 
cycle phases were defined by nuclear volume as shown. A total of three different experiments were 
performed. In the bar diagram mean percentage of cells in G0/1-, S- and G2/M phase of all experiments 
are depicted. Statistics was performed on all experiments and significance was defined as p<0.05 (* 
p<0.001 compared to medium control). (c) T cells were stimulated for 2, 10 or 24 hours with anti-
D3/CD28 in the presence (+) or absence (-) of 100 µM NOD. Cyclin D1-expression was assessed by 
westernblotting. The result of a representative experiment out of four is shown. 
a. 
b. c. 
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NOD does not impair early T cell activation events 
To evaluate whether the inhibitory effects of NOD on T cell activation was also noticed at the 
level of early cytokine production, intracellular cytokine staining was performed after 4 h of 
PMA/ionomycin stimulation. Expression of IL-2, TNF-α and INF-γ was more pronounced in 
the memory CD45RO population and was not largely affected by NOD (Figure 3a). It therefore 
seemed that NOD did not prevent early T cell activation events. To further substantiate this 
finding cap formation following anti-CD3/CD28 stimulation of purified CD3+ cells was 
assessed. Cap formation was defined as a clear local enrichment of CD3 on the surface of the 














Figure 3: Influence of NOD on early T cell activation events. (a) CD4+ T cells were pretreated with 
brefeldin A to block protein transport to golgi and subsequently stimulated for 4 hours with 






α or INF-γ) was assessed by FACS analysis in CD45RO+ and CD45RO- cells as described in the method 
section. In each experiment a negative control (neg ctrl) was included. The results of a representative 
experiment are depicted. A total of three independent experiments were performed with essentially the 
same results. (b) CD3+ T cells were placed on adhesive slides and subsequently stimulated for 2 hours 
with anti-CD3/CD28 beads in the presence or absence of 100 µM NOD. The cells were fixed and stained 
for CD3. Cap formation was assessed by fluorescence microscopy and defined as shown in the pictures 
to the left. The bar diagram represent mean percentage ± SD of cells that displayed cap formation in 
five random microscopic fields. A total of three independent experiments were performed. (c) T cells 
were stimulated for various time intervals with anti-CD3/CD28 in the presence (+) or absence (-) of 100 
µM of NOD. Activation of Lck and ZAP70 was assessed by westernblotting using specific antibodies 
against phosphorylated Lck (p-Lck) or ZAP70 (p-ZAP70) respectively. The blots were stripped and re-
probed with anti-Lck or anti-ZAP70 monoclonal antibodies. A total of three independent experiments 
with essentially the same results were performed. 
 
While in CD3+ cells that were not stimulated with anti-CD3/CD28 cap formation was almost 
not detected, in stimulated cells approximately 50 to 60% of the cells displayed cap formation. 
No significant differences between cells that were stimulated in the presence or absence of NOD 
were noticed (Figure 3b). Phosphorylation of the T cell receptor (TCR) signaling proteins 
ZAP70 and Lck occurred within 5 minutes of anti-CD3/CD28 stimulation and maintained to be 
phosphorylated over the observation period of 1 h. In line with the notion that NOD did not 
impair early activation events in T cells, no significant changes in the phosphorylation of 
ZAP70 or Lck were observed in the presence of NOD (Figure 3c). 
 
NOD inhibits both NF-B and AP-1 activation  
To elucidate if activation of transcription factors NF-B and AP-1 was impaired by NOD, 
nuclear proteins of PMA/ionomycin stimulated T cells were analyzed for binding activity to 
NF-κB or AP-1 consensus DNA oligonucleotides by EMSA. Already 3 h after stimulation an 
increase in NF-κB activation was observed and maximal activation occurring after 24 h of 
stimulation (Figure 4a, panel to the left). Based on competition with unlabeled NF-κB 
consensus oligonucleotides it seemed that two bands were retarded in EMSA. While the upper 
band was further shifted in the presence of NF-κB p50 antibody, and to a lesser extent by NF-
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κB p65 antibody, the lower band was not (Figure 4a, panel to the right). Nonetheless, when T 
cells were stimulated in the presence of 100 µM of NOD, both bands were clearly diminished 
(figure 4A, panel to the left). Similar as for NF-B also activation of AP-1 was impaired in the 
presence of NOD. The specificity and identity of the AP-1 retarded bands in EMSA was 
demonstrated by competition with unlabeled AP-1 oligonucleotides and supershifts using anti-
c-Fos or anti-c-Jun antibodies (Figure 4b).  
 
Figure 4: NOD impairs NF-κB- and AP-1-activation. T cells were stimulated for different time intervals 
with PMA/ionomycin in the presence (+) or absence (-) of 50 µM NOD. Nuclear protein extracts were 





complexes were separated by electrophoresis. Specificity of the bands was assessed by incubation with 
a 100x excess of unlabeled (cold) consensus and by incubation with specific monoclonal antibodies to 
induce a supershift (n.s. not specific).  A total of three different experiments with essentially the same 
results were performed. 
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Requirement of redox activity 
Because both NF-B and AP-1 are redox-dependent transcription factors we assessed to what 
extent redox-active moieties in NOD could account for its effect on T cell activation. To this 
end we synthesized N-octanoyl tyramin (NOT), which, compared to NOD, lacks one hydroxyl 
group at the aromatic ring (Figure 5a). As indicated in Figure 5b, NOD dose-dependently 
quenched the chemiluminescence signal that occured as a consequence of peroxidase-mediated 
oxidation of luminol. In contrast, NOT did not significantly change the chemiluminescence 
signal over a wide range of different concentration, suggesting that NOT cannot act as reducing 
agent. Inasmuch as NOT was not able to inhibit T cell proliferation (Figure 5c) it seemed that 
the inhibitory effect of NOD was likely mediated via its redox-active catechol structure. To 
further substantiate that reactive oxygen species (ROS) are generated during T cell activation 
and to assess if this was influenced by NOD, we measured intracellular ROS production by 
means of 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) (H2-
DCFDA). Upon anti-CD3/CD28 stimulation H2-DCFDA fluorescence intensity increased 
already after 5 minutes of stimulation and further increased at 20 minutes. In the presence of 




Figure 5a: NOD’s redoxactive properties are required for its antiproliferative effects on T cells. a) 






Figure 5(b-d): NOD’s redoxactive properties are required for its antiproliferative effects on T cells (b) 
To test the anti-oxidant capacity of NOD and NOT the luminol oxidation assay was used. Serial dilutions 
of NOD or NOT were added to 200µl of reaction mixture containing 0.005 U of horseradish peroxidase 
(HRP) and 20 µM of luminol. After addition of 0.01 % of H2O2, chemiluminescence was measured in 
relative light units (RLU) and is given as mean ± SD. (c) T cells were stimulated for three days with anti-
CD3/CD28 in the presence or absence of different concentrations of NOD or NOT. [3H]-thymidine 
incorporation was assessed as described in the method section. The results are expressed as mean [3H]-
thymidine incorporation in counts per minute (cpm) ± SD of 6 replicate wells for each condition. A total 
of three different experiments were performed with essentially the same results. (d) T cells were 
preincubated with H2DCFDA for 5 min and subsequently stimulated with anti-CD3/CD28 in the presence 
or absence of 100 µM NOD. FACS analysis was performed after 5 or 20 minutes (histogram to the right) 
following anti-CD3/CD28 stimulation. Basal fluorescence was measured in T cells that were not 
stimulated with anti-CD3/CD28 (medium, filled histogram). To the left, results are expressed as mean 
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Synergistic effect of NOD and calcineurin inhibitors on T cell proliferation  
To investigate if NOD may have a synergistic effect with calcineurin inhibitors (CNI) on T cell 
proliferation, dose-response experiments were performed with NOD alone or in combination 
with two concentrations of FK506 (Figure 6) or cyclosporine A (data not shown). As indicated 
in Figure 6 T cell proliferation was inhibited by FK506 when used either at 1 or 10 nM 
concentrations. Addition of 25 µM of NOD further decreased T cell proliferation compared to 




Figure 6: Synergy between NOD and calcineurin inhibitors on T cell proliferation. T cells were 
stimulated for 3 days with anti-CD3/CD28 in the presence of different concentrations of NOD and/or 
FK506. [3H]-thymidine incorporation was assessed as described in the methods section. Results are 
expressed as mean [3H]-thymidine incorporation in counts per minute (cpm)) ± SD of 6 replicate wells 
for each condition. A total of four different experiments were performed with essentially the same 





N-acyl dopamine derivatives (NADD) have gained prominence with the identification that these 
structures have the propensity to activate the endocannabinoid and endovanilloid systems [271]. 
Endogenous NADD, e.g. N-arachidonoyl-, N-oleoyl-, N-palmitoyl- and N-stearoyl dopamines 
are predominantly found in the brain with the highest levels in the striatum and low levels 
elsewhere [272]. In contrast to the endogenous NADD, NOD contains a short fatty acid but 
similar to endogenous NADD activates transient receptor potential vanilloid 1 receptors 
(TRPV1) [178]. This may at least partially explain the beneficial effect of NOD in ischemia-
induced acute kidney injury (AKI) [273, 274]. Apart from the activation of the endocannabinoid 
and endovanilloid systems it should also be noted that NADD have anti-inflammatory 
properties [179, 275] and, as such, are gaining interest as potential therapeutics for the treatment 
of a variety of inflammatory diseases. Since NOD has the ability to inhibit NF-κB activation 
[178] in the present study we assessed immunosuppressive properties of NOD by studying if 
NOD is able to suppress T cell activation, and more importantly, if it has synergistic effects 
with CNI on T cell proliferation. This study reveals the following findings: Firstly, NOD 
transiently inhibits T cell proliferation in a dose dependent fashion. This was reflected by a 
decreased percentage of T cells that became CD25 positive or started to express the memory 
marker CD45RO upon mitogen activation. NOD also caused G1-arrest in cell cycling, which 
was paralleled by a diminished cyclin D expression. Secondly, the T cell suppressive properties 
of NOD were most likely depending on the redox-active dopamine moiety, as NOT did not 
inhibit T cell proliferation. Thirdly, NOD did not affect early TCR signaling, e.g. 
phosphorylation of Lck and ZAP70 and CD3 capping. In contrast, activation of the redox-
dependent transcription factors NF-κB and AP-1 was profoundly impaired. Last but not least, 
NOD and CNI display a strong synergy to suppress T cell proliferation.  
Activation of the TCR/CD3 complex in T cells leads to the immediate activation of transcription 
factors that regulate a variety of activation-associated genes, e.g. cytokines and surface 
receptors. Oligomerisation of the TCR/CD3 complex and subsequent activation of 
phospholipase C-γ by specific tyrosine kinases at the lipid rafts are believed to be the initiating 
steps that finally culminate in full T cell activation [276-278]. We provide three lines of 
evidence that NOD does not impair these events. Firstly, CD3 cap formation was not prevented 
by NOD. Hence, the immunoreceptor tyrosine-based activation motif (ITAM) elements in the 
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cytoplasmic tails of the associated CD3 subunits would still be able to couple with critical 
tyrosine kinase pathways involving Lck and ZAP70 [279]. Secondly, indeed activation of both 
Lck and ZAP70 was not affected in the presence of NOD and, thirdly, cytokine production 
within the first 4 hours following T cell stimulation appeared to be normal.                                                                                                                             
Although NOD did not impair these initial T cell activation events, activation-induced ROS 
production was significantly inhibited by NOD. Because the redox-inactive NOT neither 
quenched HRP-mediated luminol oxidation nor inhibited T cell proliferation, it seems that the 
redox-active moiety of NOD is required for the suppressive effect on T cell proliferation. 
Studies performed by Kaminski et al. [280] clearly have demonstrated the importance of 
mitochondrial-derived ROS for gene expression upon TCR stimulation. TCR-triggered gene 
expression is controlled by both redox-dependent (NF-B, AP-1) and redox-independent 
transcription factors (NF-AT, SP-1, Oct-1, or CREB). Activation of NF-B and AP-1 was 
strongly diminished in the presence of NOD, albeit that the kinetics and degree of inhibition by 
NOD for each transcription factor was different. This might explain why early cytokine 
expression, e.g. IL-2, TNF-α and INF-γ, was still observed. Impaired activation of redox-
independent transcription factors in activated T cells has also been reported for other NADD 
[192], but was not studied for NOD in our study.  
                                                                                                                                                                                                                                                           
We are aware of the studies performed by Sancho et al. [192, 193] who demonstrate that N-
oleoyl- and N-arachidonoyl dopamine inhibit proliferation of Jurkat T cells. In contrast to our 
study they did not observe inhibition of NF-B binding in EMSA. In addition they observed a 
dose dependent impairment of transcriptional activity of luciferase reporter constructs under the 
control of the IL-2 or TNF-α promoter. This is also in contrast to our findings that NOD did not 
affect early IL-2 and TNF-α expression in activated T cells. Whether these differences can be 
explained by the different cells used in both studies (Jurkat T cells vs. primary T cells or 
PBMCs) or by the different composition of the NADD (long chain vs. short chain fatty acid) is 
at present unclear. Other reports also have shown that TRPV1 activation inhibits both early and 
late events in TCR-mediated T cell activation, e.g. calcium mobilization, NF-AT activation, IL-
2 gene transcription, IL-2R expression, and cell-cycle progression [281, 282]. It therefore also 
remains to be assessed to what extent TRPV1 activation is contributing to the T cell suppressive 
effect of NOD or NADD in general.                                                          
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NOD does not bind to dopaminergic receptors, yet once it is internalized it might be subjected 
to hydrolysis resulting in dopamine and octanoic acid. This therefore raises the question as to 
whether NOD mediated inhibition of T cell proliferation is due to the release of dopamine and 
engagement of dopaminergic receptors. Indeed there is clear evidence that engagement of 
dopamine (D1 and D2) receptors on T-lymphocytes result in inhibition of T cell proliferation 
[283]. Yet, in contrast to our present findings this is ZAP70 depended process, in which 
engagement of these receptors inhibits ZAP70 phophorylation. It is also noteworthy that NADD 
inhibit proliferation of Jurkat cells [28, 29] while this is not observed for dopamine [284]. 
Even though much controversy on the exact mechanism by which NADD inhibit T cell 
activation remains, endowed with a unique combination of TRPV1 agonistic-, 
immunosuppressive-, and NF-B-inhibitory properties, these compounds may find a potential 
use for the treatment of inflammatory condition, e.g. autoimmune diseases or transplant 
rejection. Although the latter can be successfully treated with CNI, the use of CNI has been 
identified as risk factor for IFTA. Consequently, immunosuppressive regimens that allow low 
CNI dosage without an increased risk for transplant loss are increasingly being studied to 
prevent or delay the rate of chronic transplant loss [285, 286]. Retrospective analyses have in 
addition demonstrated that early renal dysfunction is a predictor of IFTA, diminished graft 
survival [287] and a risk factor for post-transplant cardiovascular death [288]. Therefore any 
improvement of immunosuppressive therapy not only should focus on prevention of acute 
rejection, but also should aim at improving early renal function and prevention of IFTA. In a 
clinically relevant model of ischemia-induced AKI the use of NOD already showed a clear 
beneficial effect on renal function [289]. Yet, it still needs to be experimentally tested if NOD 
treatment of renal allograft recipients also improves renal function. Nonetheless, in keeping 
with the nephrotoxic side effects of CNI and the synergy between NOD and CNI on T cell 
suppression, NOD seems to be an interesting drug candidate for renal transplant recipients in 
this regard. Our findings clearly warrant further studies on NOD in relevant inflammatory 
models to further evaluate its potential clinical use as immunosuppressive drug. 
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